Letters Tackling conflicts of interest

BMJ tackles FDA’s mote in eye while ignoring own beam

BMJ 2011; 343 doi: http://dx.doi.org/10.1136/bmj.d5614 (Published 06 September 2011) Cite this as: BMJ 2011;343:d5614
  1. Stephen Senn, professor of statistics1
  1. 1School of Mathematics and Statistics, University of Glasgow, Glasgow G12 8QW, UK
  1. stephen.senn{at}glasgow.ac.uk

Godlee implies that the US Food and Drug Administration (FDA) should be blamed for reversing its decision when it realises it has made a mistake.1 Only two months ago an FDA panel voted to withdraw the breast cancer drug bevacizumab, which had been given “accelerated approval” in 2008.2 Fast track approval: is that foreign to the medical press? Well, ’pon my soul, what …

View Full Text

Sign in

Log in through your institution

Free trial

Register for a free trial to thebmj.com to receive unlimited access to all content on thebmj.com for 14 days.
Sign up for a free trial

Subscribe